There are 15,358 results relating to "Medicin Viagra-m"
Order by
|
Committee reports
Date published:
3 July 2019
What should primary care look like for the next generation? - The Scottish Youth Parliament Survey
Healthcare App’s should be developed through consultation with health professionals and patients; that these could be very useful for improving mental health outcomes; that security and privacy is ensured; that healthcare professionals and medicine keeps up with new technological developments; and that since healthcare Apps may not suitable for everyone, a ...
SPICe briefings
Date published:
30 May 2019
Brexit and veterinary workforce pressures - A perfect storm? - The role of vets
Diagnosis, treatment and prescription of medicines.
Companion animal and equine practice: looking after pets, leisure and sport animals.
Last updated:
26 January 2022
Common Frameworks Annexe A and B
Donated plasma, a component of blood, can be used to manufacture medicinal products like immunoglobulins, albumins and non- recombinant clotting factors (e.g.
Official Report
Meeting date:
20 June 2018
Meeting of the Parliament 20 June 2018
The next question is, that motion S5M-12856, in the name of Anas Sarwar, on access to vital medicines, as amended, be agreed to. Motion, as amended, agreed to, That the Parliament calls on the Scottish Government, as a matter of urgency, to bring NHS National Services Scotland, the Scottish Medicines Consortium and the relevant pharmaceutical companies together to deliver access to the life-prolonging medicines, Perjeta and Orkambi, for patients in Scotland who need them; notes the commitment that was made by the Scottish Government in December 2016, following the Review of Access to New Medicines (the Montgomery Review), to improve ways of negotiating with drug companies on the cost of medicines; calls for a new system of negotiation to be implemented now; welcomes the introduction of a new ultra-orphan pathway within the Scottish Medicines Consortium process that will make available, with ongoing evaluation for at least three years, medicines for the rarest conditions; notes the roll-out of the Peer Approved Clinical System in June 2018, replacing individual patient treatment requests, which allows clinicians to seek medicines for their patients that are not currently accepted for routine use by the NHS in Scotland, and which makes clear that the cost of the medicine must not be part of the decision-making process; further notes the commitment of the Scottish Government to continue to use all Pharmaceutical Price Regulation Scheme rebate funding to support access to new medicines; welcomes the commitment of the Association of the British Pharmaceutical Industry for its members to provide Scotland with the same discounts offered elsewhere in the UK for accessing medicines; believes that pharmaceutical companies should offer NHS Scotland fair prices and should properly engage with health technology assessments in order to demonstrate the clinical effectiveness of their medicines, and further calls on the Scottish Government to remove barriers to make access to new drugs easier, including the reform of the Patient Access Scheme Assessment Group.
Questions and Answers
Date answered:
20 April 2017
S5O-00887
Between 2011 to 2013, the combined acceptance rate for orphan/cancer medicines by the Scottish Medicines Consortium was 48%, and between 2014 to 2016 they approved 75% of ultra-orphan, orphan and end of life medicines.
Official Report
Meeting date:
8 June 2022
Citizen Participation and Public Petitions Committee 08 June 2022
Mesh itself has evolved over time. The Medicines and Healthcare products Regulatory Agency has looked at hernia mesh.
Last updated:
21 June 2021
Note by Clerk Developing a Work Programme
A marketing authorisation can only be issued following the completion of clinical trials that show: the medicine treats the condition it was developed for the medicine meets safety and quality standards the medicine does not cause unacceptable side effects.
SPICe briefings
Date published:
16 October 2025
Palliative care and assisted dying - Service Provision
There was an average of 0.9 WTE palliative medicine consultants per 100,000 population.
3 NHS boards had no palliative medicine consultants in their area but linked virtually with other board areas for support.
Committee reports
Date published:
30 April 2025
Stage 1 report: Assisted Dying for Terminally Ill Adults (Scotland) Bill - Views on the impact of competence issues on the Bill
She raised concerns about the designation of an approved substance to be used by those accessing assisted dying, which section 15(8) of the Bill would make provision for the Scottish Government to do via regulations:
The medicines issue—that the Scottish ministers are able to approve a substance—is fundamental to the whole bill.
Committee reports
Date published:
11 January 2024
Stage 1 Report on the Scottish Employment Injuries Advisory Council Bill - Membership and expertise
In relation to scientific expertise, Professor Ewan Macdonald, Society of Occupational Medicine, expressed that—
I think that we have enough people, but we would not replicate.
